Table 2 Projected outcomes of economic from 2023 to 2050
From: The macroeconomic burden of hepatitis C and the economic benefit of accelerated investments in China
Scenario 1: Status quo | Scenario 2: WHO coverage target achieved in 2030 | Scenario 3: WHO coverage target achieved in 2040 | Scenario 4: WHO coverage target achieved in 2050 | |
|---|---|---|---|---|
Cumulative productivity losses(billion) | 140.35(143.73,150.29) | 72.02(67.79,76.79) | 93.42(87.73,99.66) | 108.85(102.23,116.25) |
Cumulative total economic costs*(billion) | 234.89(222.29,249.07) | 141.74(134.44,149.90) | 173.56(164.43,183.66) | 196.57(186.11,208.07) |
Cost per DALY compared to status quo# | NA | Cost-saving | Cost-saving | Cost-saving |
Year investment met cost-saving* | NA | 2034 | 2036 | 2036 |